Scholar Rock Awaits FDA Decision on First Muscle-Targeted SMA Therapy — Scholar Rock Holding Corporation

Event summary

Scholar Rock's apitegromab BLA on track for FDA decision by September 30, 2026 PDUFA date.
Company has two independent fill-finish facilities ready for commercialization upon approval.
Phase 2 OPAL trial enrollment ongoing for infants and toddlers with SMA.
Phase 2 FORGE trial initiated for facioscapulohumeral muscular dystrophy (FSHD).
Q2 2026 net loss of $109.9 million, down slightly from $110.0 million in Q2 2025.

The big picture

Scholar Rock is on the cusp of a potential breakthrough with apitegromab, which could become the first muscle-targeted treatment for SMA. The company's strategic focus on myostatin biology positions it as a leader in neuromuscular disease treatment, but its success hinges on regulatory approval and commercial execution. With a strong balance sheet and ongoing clinical trials, Scholar Rock is poised to capitalize on this opportunity if key milestones are met.

What we're watching

Regulatory Approval: Whether the FDA will approve apitegromab by the September 30, 2026 PDUFA date and how this impacts commercialization timelines.
Market Expansion: The pace at which Scholar Rock can expand apitegromab's use to other neuromuscular diseases beyond SMA.
Financial Sustainability: How Scholar Rock will manage its cash burn rate post-approval and potential revenue generation from apitegromab.